Eli Lilly (LLY) Cash from Investing Activities (2009 - 2026)

Eli Lilly has reported Cash from Investing Activities for 18 years, with the latest figure at -$3.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 16.79% year-over-year to -$3.9 billion; the trailing twelve-month figure through Mar 2026 stood at -$11.5 billion (down 0.5% YoY), and the FY2025 full-year result was -$11.0 billion, down 17.95% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$3.9 billion, down from -$2.8 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was -$459.1 million in Q2 2023, with the low at -$4.0 billion in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$2.1 billion across 5 years, with a median of -$1.9 billion in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 44.45% — and 2024, when it sank 378.92%.
• Eli Lilly's Cash from Investing Activities stood at -$943.5 million in 2022, then slumped by 209.97% to -$2.9 billion in 2023, then surged by 34.32% to -$1.9 billion in 2024, then slumped by 45.87% to -$2.8 billion in 2025, then sank by 39.75% to -$3.9 billion in 2026.
• The last three Cash from Investing Activities figures came in at -$3.9 billion (Q1 2026), -$2.8 billion (Q4 2025), and -$3.0 billion (Q3 2025), per Business Quant data.